Mikhail Eydelman - Nov 7, 2024 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Signature
Mikhail Eydelman, by /s/ Peter N. Efremenko, Attorney-In-Fact
Stock symbol
PCVX
Transactions as of
Nov 7, 2024
Transactions value $
$0
Form type
4
Date filed
11/8/2024, 08:50 PM
Previous filing
Nov 6, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCVX Performance Stock Option (right to buy) Award $0 +26.1K $0.00 26.1K Nov 7, 2024 Common Stock 26.1K $102.70 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 As part of a company-wide grant to all eligible employees of the Issuer, on November 7, 2024 (the "Grant Date"), the Reporting Person was granted a performance stock option to purchase 26,125 shares of the Issuer's Common Stock at a per share exercise price of $102.70. The option is subject to (1) a service-based vesting condition (vesting as to one-third of the shares on each of the third, fourth and fifth anniversaries of the Grant Date) and (2) a performance-vesting condition (which generally requires that the trading price of the Issuer's Common Stock average, over a one-year period, is at least $154.05 (150% of the Grant Date closing price)).